Completed PHASE2 INTERVENTIONAL NCT00760370

Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone

Sponsor: Novartis

Conditions Breast Cancer Multiple Myeloma

Updated 5 times since 2017 Last updated: Dec 6, 2011 Started: Dec 31, 2008 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00760370, this PHASE2 trial focuses on Breast Cancer and Multiple Myeloma and remains completed. Sponsored by Novartis, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Odense University Hospital
Vejle Hospital

Data source: Vejle Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Odense, Denmark
• Vejle, Denmark